Recent advances in the pharmaceutical management of pain

Expert Review of Clinical Pharmacology

Volumn 2, Issue 5, 2009, Pages 543-557

  Hill, Lisa ^a   Schug, Stephan A ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Adjuvants; Advances; Analgesics; Cannabinoids; Coxibs; Iontophoresis; Ketamine; Opioids; Pain; Paracetamol

Indexed keywords

ABSTRAL; ANALGESIC AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; BUTRANS; CANNABINOID; CANNABIS; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DEXMEDETOMIDINE; DULOXETINE; EFFENTORA; ERESKA; FEN TEK; FENTANYL; FENTANYL CITRATE; GABAPENTIN; KETAMINE; LAMOTRIGINE; LIDOCAINE; LIPOSOME; MILNACIPRAN; MORPHINE; MORPHINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OSMOPHEN; OXYCODONE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PLACEBO; PREGABALIN; RAPINYL; ROFECOXIB; RYLOMINE; TAPENTADOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VERSATIS;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BACKACHE; BLURRED VISION; CANCER PAIN; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; DIABETIC NEUROPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG WITHDRAWAL; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; HUMAN; IONTOPHORESIS; KIDNEY DISEASE; LOW BACK PAIN; LOW DRUG DOSE; MIGRAINE; MULTIPLE SCLEROSIS; MUSCULOSKELETAL PAIN; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; PAIN; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL CORD INJURY; TOXICITY;

EID: 70549088936     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.25     Document Type: Review

References (161)

1. Merskey H. The taxonomy of pain. Med. Clin. North Am. 91(1), 13-20, vii (2007).
2. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J. Pain 10(4), 287-333 (2006).
3. Eisenach JC, Pan PH, Smiley R et al. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain 140(1), 87-94 (2008).
4. Poleshuck EL, Katz J, Andrus CH et al. Risk factors for chronic pain following breast cancer surgery: a prospective study. J. Pain 7(9), 626-634 (2006). (Pubitemid 44291598)
5. Hudcova J, McNicol E, Quah C, Lau J, Carr DB. Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain. Cochrane Database Syst. Rev. 4, CD003348 (2006). (Pubitemid 46841281)
6. Ashburn MA, Ogden LL, Zhang J, Love G, Basta SV. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J. Pain 4(6), 291-297 (2003). (Pubitemid 37013019)
7. Sathyan G, Guo C, Sivakumar K, Gidwani S, Gupta S. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr. Med. Res. Opin. 21(12), 1961-1968 (2005).
8. Freynhagen R, von Giesen HJ, Busche P et al. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J. Pain Symptom Manage. 30(3), 289-297 (2005). (Pubitemid 41354935)
9. Chelly JE, Grass J, Houseman TW, Minkowitz H, Pue A. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial. Anesth. Analg. 98(2), 427-433 (2004). (Pubitemid 38129392)
10. Koo PJ. Postoperative pain management with a patient-controlled transdermal delivery system for fentanyl. Am. J. Health Syst. Pharm. 62(11), 1171-1176 (2005).
11. Viscusi ER, Siccardi M, Damaraju CV, Hewitt DJ, Kershaw P. The safety and efficacy of fentanyl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management: an analysis of pooled data from three randomized, active-controlled clinical studies. Anesth. Analg. 105(5), 1428-1436 (2007). •• Provides a good overview of the relevant trials of iontophoretic transdermal systems fentanyl.
12. Rawal N, Langford RM. Current practices for postoperative pain management in Europe and the potential role of the fentanyl HCl iontophoretic transdermal system. Eur. J. Anaesthesiol. 24(4), 299-308 (2007). (Pubitemid 46270963)
13. Sathyan G, Zomorodi K, Gidwani S, Gupta S. The effect of dosing frequency on the pharmacokinetics of a fentanyl HCl patient-controlled transdermal system (PCTS). Clin. Pharmacokinet. 44(Suppl. 1) 17-24 (2005). (Pubitemid 41626713)
14. Shelley K, Paech MJ. The clinical applications of intranasal opioids. Curr. Drug Deliv. 5(1), 55-58 (2008). • Assessment of the intranasal route of administration for opioids.
15. Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann. Emerg. Med. 49(3), 335-340 (2007). (Pubitemid 46298611)
16. Borland ML, Bergesio R, Pascoe EM, Turner S, Woodger S. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: a randomised double blind crossover study. Burns 31(7), 831-837 (2005). (Pubitemid 41394138)
17. Paech MJ, Lim CB, Banks SL, Rucklidge MW, Doherty DA. A new formulation of nasal fentanyl spray for postoperative analgesia: a pilot study. Anaesthesia 58(8), 740-744 (2003).
18. Carr DB, Goudas LC, Denman WT et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 108(1-2), 17-27 (2004).
19. Christensen K, Rogers E, Green GA et al. Safety and efficacy of intranasal ketamine for acute postoperative pain. Acute Pain 9(4), 183-192 (2007). (Pubitemid 350161371)
20. Mystakidou K, Katsouda E, Parpa E, Vlahos L, Tsiatas ML. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. Drug Deliv. 13(4), 269-276 (2006). (Pubitemid 43739138)
21. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J. Clin. Pharmacol. 47(3), 343-350 (2007). (Pubitemid 46294716)
22. Heit HA, Gourlay DL. Buprenorphine: new tricks with an old molecule for pain management. Clin. J. Pain 24(2), 93-97 (2008).
23. Al-Ghananeem AM, Malkawi AH, Crooks PA. Effect of pH on sublingual absorption of oxycodone hydrochloride. AAPS PharmSciTech 7(1), E23 (2006).
24. Perez J, Ribera MV. Managing neuropathic pain with Sativex: a review of its pros and cons. Expert Opin. Pharmacother. 9(7), 1189-1195 (2008). • Critical review of the use of cannabinioids in the setting of neuropathic pain.
25. Nurmikko TJ, Serpell MG, Hoggart B et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebocontrolled clinical trial. Pain 133(1-3), 210-220 (2007). (Pubitemid 350141682)
26. Rog DJ, Nurmikko TJ, Young CA. Oromucosal δ9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin. Ther. 29(9), 2068-2079 (2007).
27. Thipphawong JB, Babul N, Morishige RJ et al. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology 99(3), 693-700; discussion 696A (2003). (Pubitemid 37051986)
28. Farr SJ, Otulana BA. Pulmonary delivery of opioids as pain therapeutics. Adv. Drug Deliv. Rev. 58(9-10), 1076-1088 (2006).
29. Ross EL, Hahn K. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain. Int. J. Clin. Pract. 62(3), 471-479 (2008). (Pubitemid 351197427)
30. Rauck RL, Bookbinder SA, Bunker TR et al. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J. Opioid. Manag. 2(3), 155-166 (2006).
31. Viscusi ER, Martin G, Hartrick CT, Singla N, Manvelian G. Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. Anesthesiology 102(5), 1014-1022 (2005). (Pubitemid 40586544)
32. Viscusi ER, Kopacz D, Hartrick C, Martin G, Manvelian G. Single-dose extended-release epidural morphine for pain following hip arthroplasty. Am. J. Ther. 13(5), 423-431 (2006). (Pubitemid 44435015)
33. Hartrick CT, Martin G, Kantor G, Koncelik J, Manvelian G. Evaluation of a single-dose, extended-release epidural morphine formulation for pain after knee arthroplasty. J. Bone Joint Surg. Am. 88(2), 273-281 (2006). (Pubitemid 43185127)
34. Hartrick CT, Hartrick KA. Extendedrelease epidural morphine (DepoDur): review and safety analysis. Expert Rev. Neurother. 8(11), 1641-1648 (2008). • Good summarizing review of this new preparation for epidural use.
35. Oh C. Efficacy of tapentadol immediate release in patients with pain after bunionectomy. Presented at: American Pain Society meeting. (Eds). Tampa, FL, USA (2008)
36. Hartrick C. Analgesic Efficacy of tapentadol immediate release in patients with pain from end stage joint disease. Presented at: American Pain Society Meeting. Tampa, FL, USA (2008).
37. Oh C. Tapentadol immediate release is associated with improved gastrointestinal tolerability compared with oxycodone immediate release over 90 days in patients with lower back or osteoarthritis pain. Presented at: American Pain Society Meeting. Tampa, FL, USA (2008).
38. Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst. Rev. 3, CD003726 (2006).
39. Perrot S, Krause D, Crozes P, Naim C. Efficacy and tolerability of paracetamol/ tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study. Clin. Ther. 28(10), 1592-1606 (2006). (Pubitemid 44841978)
40. Barkin RL. Extended-release tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. Am. J. Ther. 15(2), 157-166 (2008).
41. Carville SF, Arendt-Nielsen S, Bliddal H et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann. Rheum. Dis. 67(4), 536-541 (2008). • Current recommendations for the management of the complex issues related to fibromyalgia are presented here with supporting evidence.
42. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract. Res. Clin. Rheumatol. 21(3), 499-511 (2007).
43. Sandoval JA, Furlan AD, Mailis-Gagnon A. Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects. Clin. J. Pain 21(6), 503-512 (2005). (Pubitemid 41527740)
44. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst. Rev. 4, CD003971 (2007).
45. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol. Scand. 52(7), 879-889 (2008).
46. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol. Drug Saf. 14(11), 747-753 (2005).
47. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N. Engl. J. Med. 358(22), 2332-2343 (2008). (Pubitemid 351749157)
48. Leslie JB. Alvimopan for the management of postoperative ileus. Ann. Pharmacother. 39(9), 1502-1510 (2005).
49. McNicol E, Boyce DB, Schumann R, Carr D. Efficacy and safety of mu-opioid antagonists in the treatment of opioidinduced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med. 9(6), 634-659 (2008). •• The use of peripheral opioid antagonists in the the treatment of constipation caused by opioid use.
50. Meissner W, Leyendecker P, Mueller-Lissner S et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioidinduced constipation. Eur. J. Pain 13(1), 56-64 (2009).
51. Vondrackova D, Leyendecker P, Meissner W et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J. Pain 9(12), 1144-1154 (2008).
52. Kucukemre F, Kunt N, Kaygusuz K et al. Remifentanil compared with morphine for postoperative patient-controlled analgesia after major abdominal surgery: a randomized controlled trial. Eur. J. Anaesthesiol. 22(5), 378-385 (2005). (Pubitemid 40676795)
53. Baltali S, Turkoz A, Bozdogan N et al. The efficacy of intravenous patient-controlled remifentanil versus morphine anesthesia after coronary artery surgery. J. Cardiothorac. Vasc. Anesth. 23(2), 170-174 (2008).
54. Blair JM, Dobson GT, Hill DA, McCracken GR, Fee JP. Patient controlled analgesia for labour: a comparison of remifentanil with pethidine. Anaesthesia 60(1), 22-27 (2005).
55. Volmanen P, Sarvela J, Akural EI et al. Intravenous remifentanil vs. epidural levobupivacaine with fentanyl for pain relief in early labour: a randomised, controlled, double-blinded study. Acta Anaesthesiol. Scand. 52(2), 249-255 (2008).
56. Dunn MJ, Mitchell R, Souza CD, Drummond G. Evaluation of propofol and remifentanil for intravenous sedation for reducing shoulder dislocations in the emergency department. Emerg. Med. J. 23(1), 57-58 (2006). (Pubitemid 43056366)
57. Phillips WJ, Halpin J, Jones J, McKenzie K. Remifentanil for procedural sedation in the emergency department. Ann. Emerg. Med. 53(1), 163 (2009).
58. Blancas Gomez-Casero R, Martin Delgado C, Nevado Losada E et al. Sedoanalgesia with remifentanil in definitive pacemaker implant. Med. Intensiva 30(8), 370-373 (2006). (Pubitemid 44870826)
59. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343(21), 1520-1528 (2000). (Pubitemid 30844348)
60. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: celecoxib long-term arthritis safety study. JAMA 284(10), 1247-1255 (2000). (Pubitemid 30691365)
61. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352(11), 1092-1102 (2005). (Pubitemid 40365350)
62. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am. J. Cardiol. 89(6A), 26D-32D (2002).
63. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296(13), 1633-1644 (2006). (Pubitemid 44511610)
64. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365(9458), 475-481 (2005). (Pubitemid 40215729)
65. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330(7504), 1366 (2005). (Pubitemid 40839565)
66. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 330(7504), 1370 (2005). (Pubitemid 40839570)
67. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet. Disord. 8, 73 (2007). •• Careful systematic review/meta-analysis on the contentious issue of cardiovascular risk of non-steroidal anti-inflammatory drugss.
68. Ott E, Nussmeier NA, Duke PC et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 125(6), 1481-1492 (2003). (Pubitemid 36759251)
69. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352(11), 1081-1091 (2005).
70. Schug SA, Joshi GP, Camu F, Pan S, Cheung R. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Anesth. Analg. 108(1), 299-307 (2009). • Confirmation of the cardiovascular safety of short-term use of coxibs in the perioperative setting.
71. Gan TJ, Joshi GP, Zhao SZ et al. Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. Acta Anaesthesiol. Scand. 48(9), 1194-1207 (2004).
72. Hegi TR, Bombeli T, Seifert B et al. Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. Br. J. Anaesth. 92(4), 523-531 (2004). (Pubitemid 38443853)
73. Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology 102(6), 1249-1260 (2005). •• Excellent meta-analysis confirming the role of NSAIDs as a relevant component of multimodal analgesia.
74. Gajraj NM. COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management. Curr. Top. Med. Chem. 7(3), 235-249 (2007).
75. DeMaria AN, Weir MR. Coxibs - beyond the GI tract: renal and cardiovascular issues. J. Pain Symptom Manage. 25(2 Suppl.), S41-S49 (2003).
76. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and Type 2 diabetes mellitus. Arch. Intern. Med. 165(2), 161-168 (2005).
77. Chang IJ, Harris RC. Are all COX-2 inhibitors created equal? Hypertension 45(2), 178-180 (2005).
78. Ziemer M, Wiesend CL, Vetter R et al. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch. Dermatol. 143(6), 711-716 (2007). (Pubitemid 46955729)
79. Murat I, Baujard C, Foussat C et al. Tolerance and analgesic efficacy of a new i.v. paracetamol solution in children after inguinal hernia repair. Paediatr. Anaesth. 15(8), 663-670 (2005). (Pubitemid 41623798)
80. Moller PL, Juhl GI, Payen-Champenois C, Skoglund LA. Intravenous acetaminophen (paracetamol): comparable analgesic efficacy, but better local safety than its prodrug, propacetamol, for postoperative pain after third molar surgery. Anesth. Analg. 101(1), 90-96 (2005). (Pubitemid 40853356)
81. Gorocs TS, Lambert M, Rinne T, Krekler M, Modell S. Efficacy and tolerability of ready-to-use intravenous paracetamol solution as monotherapy or as an adjunct analgesic therapy for postoperative pain in patients undergoing elective ambulatory surgery: open, prospective study. Int. J. Clin. Pract. 63(1), 112-120 (2009).
82. Sinatra RS, Jahr JS, Reynolds LW et al. Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery. Anesthesiology 102(4), 822-831 (2005).
83. Toms L, McQuay HJ, Derry S, Moore RA. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database Syst. Rev. 4, CD004602 (2008).
84. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst. Rev. 1, CD005180 (2005).
85. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br. J. Anaesth. 88(2), 199-214 (2002). (Pubitemid 34144998)
86. Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br. J. Anaesth. 94(4), 505-513 (2005). (Pubitemid 40500537)
87. Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin. Pharmacol. Ther. 79(1), 9-19 (2006). (Pubitemid 43069574)
88. Chandrasekharan NV, Dai H, Roos KL et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl Acad. Sci. USA 99(21), 13926-13931 (2002). (Pubitemid 35215482)
89. Kis B, Snipes JA, Busija DW. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J. Pharmacol. Exp. Ther. 315(1), 1-7 (2005). (Pubitemid 41380491)
90. Hogestatt ED, Jonsson BA, Ermund A et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J. Biol. Chem. 280(36), 31405-31412 (2005). (Pubitemid 41291881)
91. Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur. J. Pharmacol. 531(1-3), 280-281 (2006). (Pubitemid 43202247)
92. Pickering G, Esteve V, Loriot MA, Eschalier A, Dubray C. Acetaminophen reinforces descending inhibitory pain pathways. Clin. Pharmacol. Ther. 84(1), 47-51 (2008). (Pubitemid 351861483)
93. Pickering G, Loriot MA, Libert F et al. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin. Pharmacol. Ther. 79(4), 371-378 (2006). • Interesting study reporting that 5-HT3 antagonist anti-emetics block the analgesic effect of paracetamol, thereby suggesting a serotonergic mechanism of action of paracetamol.
94. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 60(7), 341-348 (2006). • Review of the current literature on the increasing use of low-dose ketamine to manage acute and chronic pain.
95. Webster LR, Walker MJ. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. Am. J. Ther. 13(4), 300-305 (2006).
96. Chung WJ, Pharo GH. Successful use of ketamine infusion in the treatment of intractable cancer pain in an outpatient. J. Pain Symptom Manage. 33(1), 2-5 (2007).
97. Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst. Rev. 1, CD003351 (2003).
98. Elia N, Tramer MR. Ketamine and postoperative pain - a quantitative systematic review of randomised trials. Pain 113(1-2), 61-70 (2005). (Pubitemid 40044753)
99. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst. Rev. 1, CD004603 (2006).
100. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth. Analg. 99(2), 482-495 (2004). (Pubitemid 38970424)
101. Migita RT, Klein EJ, Garrison MM. Sedation and analgesia for pediatric fracture reduction in the emergency department: a systematic review. Arch. Pediatr. Adolesc. Med. 160(1), 46-51 (2006).
102. Weinbroum AA. A single small dose of postoperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphineresistant pain. Anesth. Analg. 96(3), 789-795 (2003).
103. Joly V, Richebe P, Guignard B et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 103(1), 147-155 (2005). (Pubitemid 40943147)
104. Boezaart AP. Perineural infusion of local anesthetics. Anesthesiology 104(4), 872-880 (2006).
105. Cheng GS, Choy LP, Ilfeld BM. Regional anesthesia at home. Curr. Opin. Anaesthesiol. 21(4), 488-493 (2008).
106. Capdevila X, Ponrouch M, Choquet O. Continuous peripheral nerve blocks in clinical practice. Curr. Opin. Anaesthesiol. 21(5), 619-623 (2008).
107. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 64(9), 937-947 (2004).
108. Herrmann DN, Barbano RL, Hart- Gouleau S, Pennella-Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med. 6(5), 379-384 (2005). (Pubitemid 41727336)
109. Baron R, Mayoral V, Leijon G et al. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin. Drug Invest., 29(4), 231-241 (2009). •• Complex but excellent clinical trial in neuropathic pain; useful to clinical practice as it compares with active compounds and assesses the effects of combinations in patients failing monotherapy.
110. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118(3), 289-305 (2005). (Pubitemid 41752987)
111. Dworkin RH, O'Connor AB, Backonja M et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132(3), 237-251 (2007). •• The definitive current paper on evidencebased management of neuropathic pain.
112. Galer BS, Gammaitoni AR, Oleka N, Jensen MP, Argoff CE. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr. Med. Res. Opin. 20(Suppl 2), S5-S12 (2004). (Pubitemid 40179645)
113. Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the neuropathic pain scale. Curr. Med. Res. Opin. 20 (Suppl. 2), S13-S19 (2004). (Pubitemid 40179646)
114. Saber AA, Elgamal MH, Rao AJ, Itawi EA, Martinez RL. Early experience with lidocaine patch for postoperative pain control after laparoscopic ventral hernia repair. Int. J. Surg. 7(1), 36-38 (2008).
115. Ng HP, Nordstrom U, Axelsson K et al. Efficacy of intra-articular bupivacaine, ropivacaine, or a combination of ropivacaine, morphine, and ketorolac on postoperative pain relief after ambulatory arthroscopic knee surgery: a randomized double-blind study. Reg. Anesth. Pain Med. 31(1), 26-33 (2006). (Pubitemid 43097402)
116. Axelsson K, Gupta A, Johanzon E et al. Intraarticular administration of ketorolac, morphine, and ropivacaine combined with intraarticular patient-controlled regional analgesia for pain relief after shoulder surgery: a randomized, double-blind study. Anesth. Analg. 106(1), 328-333, table of contents (2008).
117. Harvey GP, Chelly JE, AlSamsam T, Coupe K. Patient-controlled ropivacaine analgesia after arthroscopic subacromial decompression. Arthroscopy 20(5), 451-455 (2004). (Pubitemid 38620883)
118. Parvataneni HK, Shah VP, Howard H et al. Controlling pain after total hip and knee arthroplasty using a multimodal protocol with local periarticular injections: a prospective randomized study. J. Arthroplasty 22(6 Suppl. 2), 33-38 (2007). (Pubitemid 47333011)
119. Forastiere E, Sofra M, Giannarelli D, Fabrizi L, Simone G. Effectiveness of continuous wound infusion of 0.5% ropivacaine by On-Q pain relief system for postoperative pain management after open nephrectomy. Br. J. Anaesth. 101(6), 841-847 (2008).
120. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. 4, CD005454 (2007).
121. Dick IE, Brochu RM, Purohit Y et al. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J. Pain 8(4), 315-324 (2007). (Pubitemid 46551873)
122. Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs 68(18), 2611-2632 (2008).
123. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol. 8, 29 (2008).
124. Mease PJ, Clauw DJ, Gendreau RM et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J. Rheumatol. 36(2), 398-409 (2008).
125. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin. Ther. 30(11), 1988-2004 (2008).
126. Attal N, Cruccu G, Haanpaa M et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 13(11), 1153-1169 (2006). (Pubitemid 44581463)
127. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst. Rev. 3, CD005452 (2005).
128. Guay DR. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am. J. Geriatr. Pharmacother. 3(4), 274-287 (2005).
129. Hendrich J, Van Minh AT, Heblich F et al. Pharmacological disruption of calcium channel trafficking by the a2d ligand gabapentin. Proc. Natl Acad. Sci. USA 105(9), 3628-3633 (2008).
130. Lyseng-Williamson KA, Siddiqui MA. Pregabalin: a review of its use in fibromyalgia. Drugs 68(15), 2205-2223 (2008).
131. Hayashida K, Parker R, Eisenach JC. Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. Anesthesiology 106(6), 1213-1219 (2007). (Pubitemid 46828175)
132. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain - a systematic review of randomized controlled trials. Pain 126(1-3), 91-101 (2006).
133. Tiippana EM, Hamunen K, Kontinen VK, Kalso E. Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. Anesth. Analg. 104(6), 1545-1556 (2007). • Identifies the role of gabapentinoids as a component of multimodal postoperative pain management.
134. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database Syst. Rev. 2, CD006044 (2007).
135. Azad SC, Rammes G. Cannabinoids in anaesthesia and pain therapy. Curr. Opin. Anaesthesiol. 18(4), 424-427 (2005).
136. Wissel J, Haydn T, Muller J et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J. Neurol. 253(10), 1337-1341 (2006). (Pubitemid 44691559)
137. Pinsger M, Schimetta W, Volc D et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain - a randomized controlled trial. Wien Klin Wochenschr. 118(11-12), 327-335 (2006). (Pubitemid 44113611)
138. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J. Pain 9(2), 164-173 (2008).
139. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 336(7637), 199-201 (2008). (Pubitemid 351212676)
140. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin. Pharmacother. 7(5), 607-615 (2006).
141. Lin TF, Yeh YC, Lin FS et al. Effect of combining dexmedetomidine and morphine for intravenous patientcontrolled analgesia. Br. J. Anaesth. 102(1), 117-122 (2009).
142. Unlugenc H, Gunduz M, Guler T, Yagmur O, Isik G. The effect of preanaesthetic administration of intravenous dexmedetomidine on postoperative pain in patients receiving patient-controlled morphine. Eur. J. Anaesthesiol. 22(5), 386-391 (2005). (Pubitemid 40676796)
143. Esmaoglu A, Mizrak A, Akin A, Turk Y, Boyaci A. Addition of dexmedetomidine to lidocaine for intravenous regional anaesthesia. Eur. J. Anaesthesiol. 22(6), 447-451 (2005). (Pubitemid 40862929)
144. Al-Metwalli RR, Mowafi HA, Ismail SA et al. Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic knee surgery. Br. J. Anaesth. 101(3), 395-399 (2008).
145. Dray A. Neuropathic pain: emerging treatments. Br. J. Anaesth. 101(1), 48-58 (2008).
146. Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin. Emerg. Drugs 12(1), 113-126 (2007).
147. Broad LM, Mogg AJ, Beattie RE et al. TRP channels as emerging targets for pain therapeutics. Expert Opin. Ther. Targets 13(1), 69-81 (2009).
148. Backonja M, Wallace MS, Blonsky ER et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 7(12), 1106-1112 (2008).
149. Aasvang EK, Hansen JB, Malmstrom J et al. The effect of wound instillation of a novel purified capsaicin formulation on postherniotomy pain: a double-blind, randomized, placebo-controlled study. Anesth. Analg. 107(1), 282-291 (2008).
150. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov. Today 14(1-2), 56-67 (2009).
151. Amir R, Argoff CE, Bennett GJ et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J. Pain 7 5(Suppl. 3), S1-S29 (2006).
152. Silos-Santiago I. The role of tetrodotoxinresistant sodium channels in pain states: are they the next target for analgesic drugs? Curr. Opin. Investig. Drugs 9(1), 83-89 (2008).
153. Wermeling DP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 25(8), 1084-1094 (2005).
154. McGivern JG. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov. Today 11(5-6), 245-253 (2006).
155. Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin. Cell Dev. Biol. 17(5), 592-604 (2006).
156. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol. 153(2), 319-334 (2008).
157. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. 7(5), 438-455 (2008). (Pubitemid 351649182)
158. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 10(11), 1361-1368 (2007). •• Excellent and very current review on the pathogenesis of neuropathic pain.
159. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 10(1), 23-36 (2009).
160. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 22(6), 349-359 (2008).
161. Merighi A, Salio C, Ghirri A et al. BDNF as a pain modulator. Prog. Neurobiol. 85(3), 297-317 (2008).